Special Issue "Prospects of the Prodrug Approach: From Initial Design to Clinical Application"
Deadline for manuscript submissions: closed (31 October 2021).
Interests: biopharmaceutics; modified release; dissolution; infection prevention; biopolymers
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pharmaceutics: Advances in Wound Dressings and Materials
Interests: prodrugs; drug delivery; drug targeting; oral drug absorption; biopharmaceutics; intestinal permeability; neuropharmacology; parkinson’s disease; inflammatory bowel disease
Prodrugs are an increasingly used tool for overcoming physicochemical, biopharmaceutical, pharmacokinetic, and pharmacodynamic obstacles of pharmacologically active agents. To date, it is estimated that 10% of drugs in the market are classified as prodrugs; among low-molecular-weight drugs, one third are categorized as prodrugs. The increased utilization of prodrug strategies in drug development results from an increased understanding of the biological mechanisms, enabling the smart design of prodrugs with better biopharmaceutical and safety profiles. Even though smart prodrug design is challenging, it can be faster, more practical, and more efficacious than other formulation approaches and is certainly preferable in most cases to going back to the drawing board to search for an entirely new compound. When considered at the early stages of preclinical development, the prodrug approach may save time, protect resources, and facilitate the overall drug development process. This Special Issue serves to present and highlight the most recent examples and future uses of the prodrug approach from its initial design to the clinical setting.
Prof. Dr. Barbara R. Conway
Dr. Milica Markovic
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prodrug design
- enzyme-mediated prodrug activation
- drug targeting
- drug delivery
- clinical prodrug use
- oral bioavailability